- The company believes that the study findings support its patented DehydraTECH(TM) system as being the world’s fastest-acting nicotine through oral absorption and a safer nicotine alternative for the 1.1 billion smokers of the world
- Plans for a human trial are in the design process, and Lexaria intends to use existing capital to execute the study
- The global nicotine pouch market is expected to grow to a total revenue of $21.84 billion by the end of 2027, a CAGR growth of 30.7% over the forecast period
A leader in innovative drug delivery platforms, Lexaria Bioscience (NASDAQ: LEXX) has announced the results of its recent NIC-A21-1 study on oral nicotine absorption, indicating that DehydraTECH(TM)-nicotine delivered by an oral pouch product format required two to four minutes to deliver the desired nicotine levels in blood plasma versus the 45 minutes with concentration-matched controls. Lexaria believes that the study’s findings support the world’s fastest-acting nicotine oral mucosal absorption market and offer a safer alternative for 1.1 billion smokers as a means of cessation (https://cnw.fm/r0NjQ).
The key pharmacokinetic findings of the study support a statistically significant improvement in the delivery and peak levels of absorption. As a result of the performance of this study in animals, Lexaria’s next step is to progress to a larger investigation using human volunteers. The company will compare the…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
